The basis for agonist-selective signaling was investigated by using the -opioid receptor (MOR) as a model. In the absence of agonist, MOR located within the lipid raft domains, whereas etorphine, but not morphine, induced the translocation of MOR from lipid raft to nonraft domains, similar to the action of methyl--cyclodextrin. The etorphine-induced MOR translocation required the dissociation of the receptor from G␣i2 first and then the binding of -arrestin. In contrast, the low affinity of the morphine-MOR complex for -arrestin and the rebinding of G␣i2 after GTP hydrolysis retained the complex within the lipid raft domains. Disruption of the MOR-G␣i2 interaction, either by deleting the 276 RRITR 280 sequence of MOR or knocking down the level of G␣i2, resulted in the translocation of MOR to the nonraft domains. In addition, lipid raft location of MOR was critical for G protein-dependent signaling, such as etorphine-and morphine-mediated inhibition of adenylyl cyclase activity and morphine-induced ERK phosphorylation, whereas -arrestin-dependent, etorphine-induced ERK phosphorylation required MOR to translocate into the nonraft domains. Thus, agonist-selective signaling is regulated by the location of MOR, which is determined by interactions of MOR with G proteins and -arrestin.lipid raft ͉ opioid A gonists possess different efficacies on different signaling pathways of particular receptors (1, 2). Understanding agonist-selective signaling will accelerate the development of pathway-selective drugs, which have higher efficacy and potency, but fewer side effects (2). Among the various observations of agonist-selective signaling, selectivity between G proteindependent and -arrestin-dependent pathways of G proteincoupled receptor (GPCR) agonists has been well studied (2). For example, angiotensin II (angiotensin II receptor type 1A receptor agonist) uses both the G protein-dependent and -arrestindependent pathways to induce ERK phosphorylation, whereas ICI118551 (2-adrenergic receptor agonist) and CCL19 (chemokine receptor CCR7 agonist) induce ERK phosphorylation completely via one of the two pathways (3-5). Classically, receptor-mediated activation of the G protein releases free G␥ subunits and induces GPCR kinase (GRK)-mediated receptor phosphorylation, which in turn increases the affinity of the receptor for -arrestin (6). The binding of -arrestin terminates the G protein-dependent pathway by uncoupling the G protein from the complex and activates signaling mediated by itself. Thus the activation of the -arrestin-dependent pathway requires G protein activation. However, the existence of G proteinindependent -arrestin signaling was observed with the GPCR mutants that were incapable of interacting with G proteins (7,8). How agonists select between the two pathways remains unclear.One probable mechanism is that the GPCR location within different membrane domains, such as lipid raft and nonraft domains, determines the agonist-selective signaling. The lipid raft domain is characterized as a dynamic plasma...